A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
← catalyst calendarNCT07154290 · readout in 1,391 d
Sponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
300estimated
Sites
15
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-03-18 | actual | When the study began enrolling |
| Primary completion | 2030-06-10 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-06-10 | estimated | The whole study's end, after follow-up |
| First posted | 2025-09-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Non-Small Cell Lung Cancer
- Advanced Non-Small Cell Lung Cancer
- Metastatic Non-Small Cell Lung Cancer
- Carcinoma, Non-Small-Cell Lung
Interventions
- Drug: Ubamatamab — also filed as REGN4018
- Drug: Marlotamig — also filed as REGN7075
- Drug: Sarilumab — also filed as REGN88SAR153191, KEVZARA®
Primary outcome
what the primary-completion date above is the date OFObjective response as assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
measured Up to 5 years
Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed